1. Introduction
===============

Cancers are lethal disorder with poor outcomes and increasing incidence around the world.^\[[@R1],[@R2]\]^ There are more than 100 types of cancer, such as lung cancer, breast cancer, prostate cancer, lymphoma, gastric cancer, ovarian cancer, and so on.^\[[@R3]\]^ Symptoms often vary according to the different types of cancer. A variety of factors contribute to the cancers, including, alcohol, obesity, dietary factors, and infection.^\[[@R4],[@R5]\]^ The cancer management may include chemotherapy, radiation, and/or surgery.^\[[@R6],[@R7]\]^ However, all those treatments still have limited efficacy, and also accompany lots of toxicities.^\[[@R8]\]^ Therefore, more potential therapies are still urgently needed for patients with cancers.

Green tea is a very popular and widely consumed beverage globally.^\[[@R9],[@R10]\]^ Previous studies have reported that highest green tea intake can significantly lower cancer risk.^\[[@R9]--[@R11]\]^ It contains several catechin components, also known as green tea extracts (GTE), including Epigallocatechin gallate, Epigallocatechin, Epicatechin-3-gallate, and Epicatechin.^\[[@R12]\]^ Several preclinical studies of green tea and its components are reported to show promising efficacy for the growth inhabitation of tumors with fewer adverse events.^\[[@R13],[@R14]\]^ Furthermore, a numerous of clinical trials have reported that GTE can be used to treat a large range of cancers effectively, including breast cancer, colorectal cancer, prostate cancer, ovarian cancer, liver cancer, lung cancer, lymphoma, gastric cancer, and pancreatic cancer.^\[[@R9],[@R10],[@R15]--[@R29]\]^ Presently, no systematic review study has assessed the efficacy and safety of GTE for patients with a variety of cancers. Thus, this systematic review will first investigate the efficacy and safety of GTE for cancers.

2. Methods
==========

2.1. Objective
--------------

This systematic review aims to assess the efficacy and safety of GTE for patients with cancers.

2.2. Study registration
-----------------------

The protocol of this study has been registered in PROSPERO with CRD42019125111.

2.3. Inclusion criteria for study selection
-------------------------------------------

### 2.3.1. Types of studies

All qualified randomized controlled trials (RCTs) and case-control studies will be included in this study without language or publication restrictions. However, non-clinical studies, case studies, uncontrolled studies will not be included.

### 2.3.2. Types of patients

Patients who are clinically diagnosed with cancers, including breast cancer, colorectal cancer, prostate cancer, ovarian cancer, liver cancer, lung cancer, lymphoma, gastric cancer, and pancreatic cancer will all be fully considered for inclusion without the restrictions of race, gender, and age. However, patients with other severe disorders that may affect the outcome measurements will be excluded, such as acute heart failure, severe stroke and so on.

### 2.3.3. Types of interventions

Any types of GTE therapy will be considered for inclusion, except the combination of GTE with other interventions. Control therapy can be any treatments, except the GTE, or any kinds of green tea.

### 2.3.4. Types of outcome measurements

The primary outcome is measured by overall response rate (ORR). The secondary outcomes are assessed by overall survival (OS), progression-free survival (PFS), the disease control rate (DCR), and any adverse events.

2.4. Search methods for the identification of studies
-----------------------------------------------------

### 2.4.1. Search electronic bibliographic databases

We will search Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED), and Chinese databases of Chinese Biomedical Literature Database (CBM) up to February 1, 2019 using a comprehensive strategy. Reference lists of relevant studies will also be identified for potential consideration. The sample of comprehensive search strategy for CENTRAL is presented in Table [1](#T1){ref-type="table"}. Similar comprehensive search strategies will also applied to any other electronic databases.

###### 

Search strategy for CENTRAL database.
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### 2.4.2. Search for other resources

References lists of relevant trials will also be searched to avoid missing any potential studies.

2.5. Data collection and extraction
-----------------------------------

### 2.5.1. Study selection

Two authors will independently screen the title and abstract of all identified studies for eligibility. Then, full-texts will be read for further selection in accordance with the predefined eligibility criteria. Any disagreements between 2 authors will be solved by consulting a third author. The whole process of study selection will be presented in Figure [1](#F1){ref-type="fig"}.

![Flowchart of study selection.](medi-98-e15117-g002){#F1}

### 2.5.2. Data extraction and management

Two authors will independently extract data according to the predefined and standardized data extraction form. This form comprises of the data of study characteristics, such as title, first author, published year, location; patient populations, such as race, age, gender, eligibility criteria; study design, such as sample size, randomization, concealment, and blinding; interventions, such as dosage, frequency, and duration; and outcomes, such as primary, secondary, and safety outcome measurements. All divergences regarding the data extraction between 2 authors will be solved by a third author through discussion.

### 2.5.3. Dealing with missing data

Any missing data will be inquired by contacting the primary authors. If we can not receive those data, then we will only analyze the available data and will discuss its potential impacts.

2.6. Risk of bias assessment
----------------------------

We will use Cochrane Risk of Bias Tool to evaluate the risk of bias for each included study. This tool assesses the risk of bias in 7 domains, and each domain will be determined as high, unclear, or low risk of bias. Any dissimilarity regarding the risk of bias assessment between 2 authors will be settled down by consensus with a third author.

2.7. Statistical analysis
-------------------------

RevMan 5.3 software will be utilized to pool the data and conduct meta-analysis in this study.

### 2.7.1. Measurement of treatment effect

Dichotomous data will be shown as risk ratio and 95% confidence intervals (CIs). Continuous data will be demonstrated as mean difference or standardized mean difference and 95% CIs.

### 2.7.2. Assessment of heterogeneity

Cochrane *I*^2^ test will be used to assess the heterogeneity. If the value of *I*^2^ \>50%, significant heterogeneity is considered. Otherwise, if the value of *I*^2^ ≤50%, acceptable heterogeneity is considered.

### 2.7.3. Data synthesis

If acceptable heterogeneity will be detected, a fixed-effect model will be used to pool and meta-analysis will be performed. Otherwise, if significant heterogeneity will be identified, a random-effect model will be applied, and subgroup analysis will be carried out. Meta-analysis will be conducted according to the results of subgroup analysis. If there is still significant heterogeneity after the subgroup analysis, meta-analysis will not be conducted. However, a narrative summary will be described.

### 2.7.4. Subgroup analysis

Subgroup analysis will be carried out to identity any reasons that may cause the substantial heterogeneity. It will be performed based on the different treatments, controls, and outcome measurements.

### 2.7.5. Sensitivity analysis

Sensitivity analysis will conducted to check the stability of the pooled results by removing the low quality of included studies.

### 2.7.6. Publication biases

If there will be more than 10 qualified studies are included, Funnel plot and Egger linear regression test will be operated to identify any potential publication biases.

3. Discussion
=============

Currently, no systematic review has been performed regarding the efficacy and safety of GTE for the treatment of patients with cancers. In this systematic review, we will first investigate the efficacy and safety of GTE for a variety of cancers. The results of this study will summarize the latest evidence for assessing the efficacy and safety of GTE for the treatment of cancers. Its findings may provide helpful evidence for both patients and clinicians.
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